Literature DB >> 11407656

False serum calcitonin high levels using a non-competitive two-site IRMA.

M Tommasi1, A Brocchi, A Cappellini, S Raspanti, M Mannelli.   

Abstract

Dual site antibody-base immunoassays are commonly used in clinical laboratories to quantify the CT serum concentrations as a specific and sensitive marker of medullary thyroid carcinoma (MTC). Heterophile antibodies can interfere with these assays, however, and cause erroneous results. In order to avoid this interference, immobilized and conjugated antibodies from two different animal species or immunoreactive antibody fragments, as well as the addition of non-immune globulins, are generally included among the assay reagents. We describe the case of a 73-year-old man affected by a multinodular goiter, who showed high basal CT plasma levels as measured by a monoclonal antibody based IRMA. The finding of negative results for the presence of MTC at fine needle aspiration (FNA) and the mild increase observed in plasma CT during a pentagastrin (Pg) stimulation test, suggested that the high CT levels might depend on a cross-reaction with heterophilic antibodies. In fact, after the addition of the heterophilic blocking tube (HBT) to each specimen, the CT levels markedly decreased by more than 80% (average decrease+/-SE= 87.6+/-2.668%). Such a decrease strongly suggests that in our case the routinely used F(ab')2 fragments were unable to eliminate all of the interference and that the elevated serum CT levels might have been caused by human heterophilic antibodies. In conclusion, these results indicate a novel cause of CT false positivity, suggesting that high serum CT levels, when combined with a slight increase during Pg stimulation, should be critically interpreted in view of the possible presence of heterophilic antibodies in the specimens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407656     DOI: 10.1007/BF03343873

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

Review 1.  Antibody multispecificity in immunoassay interference.

Authors:  S S Levinson
Journal:  Clin Biochem       Date:  1992-04       Impact factor: 3.281

2.  Heterophilic antibodies remain a problem for the immunoassay laboratory.

Authors:  G Ward; L McKinnon; T Badrick; P E Hickman
Journal:  Am J Clin Pathol       Date:  1997-10       Impact factor: 2.493

3.  Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.

Authors:  F Pacini; M Fontanelli; L Fugazzola; R Elisei; C Romei; G Di Coscio; P Miccoli; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1994-04       Impact factor: 5.958

4.  False increase in C-reactive protein attributable to heterophilic antibodies in two renal transplant patients treated with rabbit antilymphocyte globulin.

Authors:  J F Benoist; D Orbach; D Biou
Journal:  Clin Chem       Date:  1998-09       Impact factor: 8.327

5.  Heterophilic antibodies produce spuriously elevated concentrations of the MB isoenzyme of creatine kinase in a selected patient population.

Authors:  R C Sosolik; C L Hitchcock; W J Becker
Journal:  Am J Clin Pathol       Date:  1997-05       Impact factor: 2.493

6.  A new interference in some digoxin assays: anti-murine heterophilic antibodies.

Authors:  C Liendo; J K Ghali; S W Graves
Journal:  Clin Pharmacol Ther       Date:  1996-11       Impact factor: 6.875

7.  The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families.

Authors:  D J Marsh; D McDowall; V J Hyland; S D Andrew; M Schnitzler; E L Gaskin; D F Nevell; T Diamond; L Delbridge; P Clifton-Bligh; B G Robinson
Journal:  Clin Endocrinol (Oxf)       Date:  1996-02       Impact factor: 3.478

8.  Eliminating interference from heterophilic antibodies in a two-site immunoassay for creatine kinase MB by using F(ab')2 conjugate and polyclonal mouse IgG.

Authors:  H C Vaidya; B G Beatty
Journal:  Clin Chem       Date:  1992-09       Impact factor: 8.327

9.  Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects--incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme.

Authors:  R J Thompson; A P Jackson; N Langlois
Journal:  Clin Chem       Date:  1986-03       Impact factor: 8.327

10.  Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.

Authors:  N Barbot; C Calmettes; I Schuffenecker; J P Saint-André; B Franc; V Rohmer; P Jallet; J C Bigorgne
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958

View more
  9 in total

1.  Interference causes false high calcitonin levels with a commercial assay.

Authors:  C Bieglmayer; B Niederle; H Vierhapper
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

2.  Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study.

Authors:  G Papi; S M Corsello; K Cioni; A M Pizzini; S Corrado; C Carapezzi; G Fadda; A Baldini; C Carani; A Pontecorvi; E Roti
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

Review 3.  Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.

Authors:  Giuseppe Costante; Cosimo Durante; Zélia Francis; Martin Schlumberger; Sebastiano Filetti
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

4.  [Diagnostic laboratory guideline for assessment of functional disorders and diseases of the thyroid gland].

Authors:  Christian Bieglmayer; Wolfgang Buchinger; Manuela Födinger; Mathias M Müller; Pranav Sinha; Marietta Vogl; Michael Weissel; Wolfgang Zechmann
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

5.  Heterophilic antibodies causing falsely high serum calcitonin values.

Authors:  P D Papapetrou; A Polymeris; H Karga; G Vaiopoulos
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

6.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

7.  Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.

Authors:  Hans Hg Verbeek; Jan Willem B de Groot; Wim J Sluiter; Anneke C Muller Kobold; Edwin R van den Heuvel; John Tm Plukker; Thera P Links
Journal:  Cochrane Database Syst Rev       Date:  2020-03-16

Review 8.  Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Marcelo Augusto Santos; Marcos R Tavares; Rodrigo A Toledo; Joya Emilie de Menezes Correia-Deur
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

9.  Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association.

Authors:  Rossella Elisei; Cristina Romei
Journal:  Thyroid Res       Date:  2013-03-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.